Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.
Experts explore strategies to increase the number of patients benefiting from multidisciplinary team (MDT) collaboration and the factors MDTs consider when deciding between surgical resection and nonsurgical options for early-stage NSCLC.
Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.